Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Inclusion Criteria

• •Age ≤40 years.
• •Diagnoses-patients with the following hematologic malignancies and bone marrow failure syndromes:
• •* Acute myelogenous leukemia-induction failure, relapse, second or greater complete remission (CR)
• •* Acute lymphocytic leukemia-induction failure, relapse, second or greater CR, first CR with t(9;22), t(8;14), or t(4;11)
• •* Non-Hodgkin's lymphoma (intermediate or high grade) which has failed to achieve CR with at least two induction regimens, relapse, second or greater CR
• •* Multiple myeloma with poor prognostic features (elevated 0-2 microglobulin or high labeling index)
• •* Hodgkin's disease in relapse or which fails to achieve CR after two chemotherapy regimens
• •* Congenital or acquired bone marrow failure - poorly responsive to or intolerant of current therapy
• •* Myelodysplastic syndrome of all subtypes except refractory anemia (RA)
• •Patient has a haploidentical family member that meets medical criteria for donation.
• •Eligibility for other transplant types:
• •* Patient considered likely to have clinical deterioration and rapid disease progression during an unrelated donor search, or
• •* Patient who has already had an unproductive donor search or
• •* Patient ineligible for or has refused autologous transplant
• •Adequate renal and hepatic function for age:
• •* Serum creatinine \<2 x ULN
• •* Alanine aminotransferase (ALT, SGPT) x ULN
• •* Aspartate aminotransferase (AST, SGOT) x ULN
• •* Total bilirubin 5\_2 x ULN except if bilirubin is elevated due to Gilbert's syndrome or hemolytic anemia
• •Adequate cardiac and pulmonary function for age.
• •ECOG Performance Status 0, 1, or 2 or Lansky performance scale \>50% for patients \<16 years of age.
• •Voluntary witnessed written informed consent. Children will be asked for assent where appropriate.
• •The patient, if female, must be post-menopausal, premenarcheal, or sterile, or if the patient is of childbearing potential, she must be practicing a method of birth control considered effective and medically acceptable by the investigator for a minimum of 1 month prior to study entry and at least 2 months after the study end.
• •Patient must have undergone successful leukapheresis to obtain adequate antigen presenting cells.
• •Any patient who enters the study in a relapse state, with evidence of end organ (pulmonary, renal, or hepatic) toxicity, or with recent recovery from infection, who may potentially have little benefit from this protocol, must have his/her eligibility status discussed with the Principal Investigator.
• •Patient must have life expectancy of at least 12 weeks.